Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

NCT00228397 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: CCI-779

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer